Association of urinary phthalate metabolites with all-cause and cardiovascular disease mortality among adults with diabetes mellitus: National Health and Nutrition Examination Survey 2005–2014

Background The study regarding phthalate metabolites and mortality among diabetes mellitus (DM) is limited. We aimed to examine the association of urinary phthalate metabolites with all-cause and cardiovascular disease (CVD) mortality among adults with DM. Methods This study included 8,931 adults from the National Health and Nutrition Examination Survey (NHANES) from 2005–2006 to 2013–2014. Mortality data were linked to National Death Index public access files through December 31, 2015. Cox proportional hazard models were used to estimate hazard ratios (HR) and 95% confidences (CIs) for mortality. Results We identified 1,603 adults with DM [mean ± SE age, 47.08 ± 0.30 years; 50.5% (833) were men]. Mono-(carboxynonyl) phthalate (MCNP), mono-2-ethyl-5-carboxypentyl phthalate (MECPP), and the sum of Di (2-ethylhexyl) phthalate (DEHP) metabolites (∑DEHP) were positively associated with DM (MCNP: OR = 1.53, 95%CI = 1.16–2.01; MECPP: OR = 1.17, 95% CI = 1.03–1.32; ∑DEHP: OR = 1.14, 95% CI = 1.00–1.29). Among DM patients, mono-(3-carboxypropyl) phthalate (MCPP) was associated with a 34% (HR 1.34, 95% CI 1.12–1.61) increased risk of all-cause mortality while the HRs (95%CI) of CVD mortality were 2.02 (1.13–3.64) for MCPP, 2.17 (1.26–3.75) for mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), 2.47 (1.43–4.28) for mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP), 2.65 (1.51–4.63) for MECPP, and 2.56 (1.46–4.46) for ∑DEHP, respectively. Conclusion This study is an academic exploration of the association between urinary phthalate metabolites and mortality among adults with DM, suggesting that exposure to phthalates might be associated with an increased risk of all-cause and CVD mortality in DM. These findings suggest that patients with DM should carefully use plastics products.

[1]  B. Duncan,et al.  IDF diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045 , 2021, Diabetes Research and Clinical Practice.

[2]  Xu Zhu,et al.  Association of urinary phthalate metabolites with cardiovascular disease among the general adult population. , 2021, Environmental research.

[3]  Yingli Lu,et al.  Exposure to phthalates and cardiovascular diseases in Chinese with type 2 diabetes , 2021, Environmental Science and Pollution Research.

[4]  E. Cairrão,et al.  Phthalates Implications in the Cardiovascular System , 2020, Journal of cardiovascular development and disease.

[5]  J. Manson,et al.  Urinary concentrations of phthalate biomarkers and weight change among postmenopausal women: a prospective cohort study , 2019, Environmental Health.

[6]  Nicolle S. Tulve,et al.  Urinary phthalate metabolites and metabolic syndrome in U.S. adolescents: Cross-sectional results from the National Health and Nutrition Examination Survey (2003-2014) data. , 2019, International journal of hygiene and environmental health.

[7]  F. Neffati,et al.  Di (2-ethylhexyl) phthalate induces cardiac disorders in BALB/c mice , 2019, Environmental Science and Pollution Research.

[8]  2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019 , 2018, Diabetes Care.

[9]  J. Meeker,et al.  Associations between school lunch consumption and urinary phthalate metabolite concentrations in US children and adolescents: Results from NHANES 2003-2014. , 2018, Environment international.

[10]  Bo Chen,et al.  The role of oxidative stress in cardiometabolic risk related to phthalate exposure in elderly diabetic patients from Shanghai. , 2018, Environment international.

[11]  R. Henning Type-2 diabetes mellitus and cardiovascular disease. , 2018, Future cardiology.

[12]  R. Dales,et al.  The associations between phthalate exposure and insulin resistance, β-cell function and blood glucose control in a population-based sample. , 2018, The Science of the total environment.

[13]  M. Trenell,et al.  The cardio-metabolic impact of taking commonly prescribed analgesic drugs in 133,401 UK Biobank participants , 2017, PloS one.

[14]  Lei Wang,et al.  Exposure to phthalates in patients with diabetes and its association with oxidative stress, adiponectin, and inflammatory cytokines. , 2017, Environment international.

[15]  N. Kamimura,et al.  Phthalates impact human health: Epidemiological evidences and plausible mechanism of action. , 2017, Journal of hazardous materials.

[16]  Alexandros G. Asimakopoulos,et al.  Urinary concentrations of 25 phthalate metabolites in Brazilian children and their association with oxidative DNA damage. , 2017, The Science of the total environment.

[17]  A. Calafat,et al.  Prenatal phthalate exposure and 8-isoprostane among Mexican-American children with high prevalence of obesity. , 2017, Journal of developmental origins of health and disease.

[18]  A. Sinclair,et al.  Examining factors associated with excess mortality in older people (age ≥ 70 years) with diabetes – a 10‐year cohort study of older people with and without diabetes , 2017, Diabetic medicine : a journal of the British Diabetic Association.

[19]  D. Flynn,et al.  Urinary levels of phthalate metabolites and cardiovascular disease mortality (NHANES, 1999-2008). , 2016, International journal of hygiene and environmental health.

[20]  E. Cairrão,et al.  The effects of phthalates in the cardiovascular and reproductive systems: A review. , 2016, Environment international.

[21]  G. Landman,et al.  Mortality trends in diabetes mellitus. , 2015, JAMA internal medicine.

[22]  J. Mindell,et al.  Diabetes mellitus and mortality from all-causes, cancer, cardiovascular and respiratory disease: evidence from the Health Survey for England and Scottish Health Survey cohorts. , 2014, Journal of diabetes and its complications.

[23]  D. Mattison,et al.  Do phthalates act as obesogens in humans? A systematic review of the epidemiological literature , 2014, Critical reviews in toxicology.

[24]  M. Longnecker,et al.  Misuse of blood serum to assess exposure to bisphenol A and phthalates , 2013, Breast Cancer Research.

[25]  I. Shiue Urine phthalate concentrations are higher in people with stroke: United States National Health and Nutrition Examination Surveys (NHANES), 2001–2004 , 2013, European journal of neurology.

[26]  N. Lee,et al.  Phthalate Exposure Changes the Metabolic Profile of Cardiac Muscle Cells , 2012, Environmental health perspectives.

[27]  V. Basevi,et al.  Standards of Medical Care in Diabetes—2012 , 2011, Diabetes Care.

[28]  A. Calafat,et al.  Personal care product use and urinary levels of phthalate metabolites in Mexican women. , 2011, Environment international.

[29]  Vilmundur Gudnason,et al.  Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death , 2011 .

[30]  L. Giudice,et al.  Endocrine-disrupting chemicals: an Endocrine Society scientific statement. , 2009, Endocrine reviews.

[31]  M. Dalgaard,et al.  Impact of diisobutyl phthalate and other PPAR agonists on steroidogenesis and plasma insulin and leptin levels in fetal rats. , 2008, Toxicology.

[32]  A. Calafat,et al.  Temporal variability in urinary concentrations of phthalate metabolites, phytoestrogens and phenols among minority children in the United States. , 2008, Environmental research.

[33]  A. Calafat,et al.  Quantification of 22 phthalate metabolites in human urine. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[34]  Bernhard Liebl,et al.  Occurrence and daily variation of phthalate metabolites in the urine of an adult population. , 2007, International journal of hygiene and environmental health.

[35]  Antonia M. Calafat,et al.  Integrating Biomonitoring Exposure Data into the Risk Assessment Process: Phthalates [Diethyl Phthalate and Di(2-ethylhexyl) Phthalate] as a Case Study , 2006, Environmental health perspectives.

[36]  K. Hungerbühler,et al.  What Are the Sources of Exposure to Eight Frequently Used Phthalic Acid Esters in Europeans? , 2006, Risk analysis : an official publication of the Society for Risk Analysis.

[37]  A. Calafat,et al.  PHTHALATES AND HUMAN HEALTH , 2005, Occupational and Environmental Medicine.

[38]  A. Calafat,et al.  Determination of 16 phthalate metabolites in urine using automated sample preparation and on-line preconcentration/high-performance liquid chromatography/tandem mass spectrometry. , 2005, Analytical chemistry.

[39]  L. Aerts,et al.  Lifetime consequences of abnormal fetal pancreatic development , 2003, The Journal of physiology.

[40]  R. Rubin,et al.  Some pharmacologic and toxicologic effects of di-2-ethylhexyl phthalate (DEHP) and other plasticizers. , 1973, Environmental health perspectives.

[41]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[42]  Robert C. Wolpert,et al.  A Review of the , 1985 .